カテゴリ： GlobalData, アメリカ, 企業調査

Lexicon Pharmaceuticals Inc (LXRX)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Lexicon Pharmaceuticals Inc (LXRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10072
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：64
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Lexicon Pharmaceuticals Inc (Lexicon) is a biopharmaceutical company, which focuses on the discovery, development and commercialization of innovative treatments for human diseases. The company has advanced multiple drug candidates into clinical development and has clinical-stage drug program sotagliflozin (LX4211) for type 1 and type 2 diabetes and its approved product Xermelo (telotristat ethyl) for the treatment of carcinoid syndrome. Lexicon’s clinical and preclinical development programs, LX2761 and LX9211 are focused at treating diabetes and neuropathic pain respectively. Lexicon has its laboratory at Texas. It has business collaborations with several pharmaceutical and biotechnology companies. Lexicon is headquartered at The Woodlands, Texas, the US.

Lexicon Pharmaceuticals Inc (LXRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Licensing Agreements 13
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Equity Offering 18
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For US$40 Million 24
Debt Offering 25
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc – Key Competitors 27
Lexicon Pharmaceuticals Inc – Key Employees 28
Lexicon Pharmaceuticals Inc – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Nov 01, 2018: Lexicon Pharmaceuticals reports third quarter 2018 financial results and provides a business update 30
Jul 30, 2018: Lexicon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides a Business Update 32
May 03, 2018: Lexicon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides a Business Update 33
Feb 22, 2018: Lexicon Pharmaceuticals Announces Fourth Quarter and Full-year 2017 Financial Results 35
Nov 08, 2017: Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides a Business Update 38
Aug 01, 2017: Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business Update 39
May 02, 2017: Lexicon Pharmaceuticals Reports First Quarter 2017 Financial Results And Provides A Business Update 41
Mar 03, 2017: Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 43
Product News 45
06/10/2017: Sotagliflozin Data from Pivotal inTandem1 and inTandem2 Studies in Patients with Type 1 Diabetes Presented at ADA 2017 45
06/05/2017: Lexicon Pharmaceuticals To Present New Clinical Data At 77th American Diabetes Association Scientific Sessions 47
03/29/2018: EMA to Review Sotagliflozin as Potential Treatment for type 1 diabetes 48
03/06/2017: Diplomat to Dispense XERMELO for Patients With Carcinoid Syndrome Diarrhea 49
03/01/2017: XERMELO (telotristat ethyl) Approved for the Treatment of Carcinoid Syndrome, Available for Order Immediately at Biologics 50
02/28/2017: FDA approves Xermelo for carcinoid syndrome diarrhea 51
Product Approvals 52
May 22, 2018: FDA to Review Zynquista (sotagliflozin) as Potential Treatment for Type 1 Diabetes 52
Mar 26, 2018: Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults with Type 1 Diabetes 53
Clinical Trials 54
Sep 13, 2017: New England Journal of Medicine Publishes Data from Phase 3 inTandem3 Study of Sotagliflozin in Patients with Type 1 Diabetes 54
Sep 08, 2017: Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTandem2 Studies Of Sotagliflozin 56
Sep 05, 2017: Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meeting 57
Aug 15, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of Sotagliflozin 58
Jun 09, 2017: Lexicon Pharmaceuticals Reports Positive Top-Line Results In Phase 3 inTandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes 60
May 11, 2017: Lexicon Pharmaceuticals Reports Additional Positive Data from Pivotal InTandem1 Phase 3 Study for Sotagliflozin in Patients with Type 1 Diabetes 61
Jan 09, 2017: Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Nuevolution Enters Into Agreement With Howard Hughes Medical Institute, Lexicon Pharma And Duke University For Drug Discovery 11
Sanofi Amends Licensing Agreement with Lexicon Pharma 13
Lexicon Pharma Expands Licensing Agreement with Ipsen 15
Lexicon Pharma Expands Licensing Agreement with Ipsen for Telotristat Etiprate 16
Lexicon Pharma Files Registration Statement for Public Offering of Shares 18
Lexicon Pharma Raises USD4.7 Million in Private Placement of Shares 19
Lexicon Pharma Raises USD150 Million in Private Placement of Shares 20
Lexicon Pharma Raises USD50 Million in Public Offering of Shares 22
Lexicon Pharma Completes Public Offering Of Common Stock For US$40 Million 24
Lexicon Pharma Raises USD80 Million in Private Placement of Notes Due 2021 25
Lexicon Pharmaceuticals Inc, Key Competitors 27
Lexicon Pharmaceuticals Inc, Key Employees 28
Lexicon Pharmaceuticals Inc, Subsidiaries 29

List of Figures
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lexicon Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Lexicon Pharmaceuticals Inc (LXRX)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • RAK Petroleum Plc (RAKP)：企業の財務・戦略的SWOT分析
    Summary RAK Petroleum Plc (RAK Petroleum), a subsidiary of RAK Investment Auhtority, is oil and gas company that transports and trades oil, gas and petrochemicals. The company carries out upstream, midstream and downstream activities. It operates its projects in the Middle East and Africa. RAK Petro …
  • Aclara Technologies LLC-エネルギー分野：企業M&A・提携分析
    Summary Aclara Technologies LLC (Aclara), as a subsidiary of Sun Capital Partners, Inc. The company designs, develops and commercializes Advanced Metering Infrastructure (AMI) solutions for data value management, customer communication and device networking activities. It provides an array of custom …
  • Huron Consulting Group Inc：企業の戦略・SWOT・財務分析
    Huron Consulting Group Inc - Strategy, SWOT and Corporate Finance Report Summary Huron Consulting Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Nostra Terra Oil and Gas Company plc (NTOG)：企業の財務・戦略的SWOT分析
    Summary Nostra Terra Oil and Gas Company Plc (NTOG) is an oil and gas company. The company explores, produces, and develops oil and gas properties across the US. It holds interest in operating and non-operating working interests in its projects located in New Mexico, Permian Basin located in West Te …
  • Genentech Inc-製薬・医療分野：企業M&A・提携分析
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that develops and markets medicines to address serious medical needs. Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST2 for ast …
  • Boston Children’s Hospital-医療機器分野：企業M&A・提携分析
    Summary Boston Children's Hospital (Boston Children’s) is the pediatric medical center that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary pediatric teaching affiliate of Harvard Medical School. The organizatio …
  • nLife Therapeutics SL：製薬・医療：M&Aディール及び事業提携情報
    Summary nLife Therapeutics SL (nLife Therapeutics) is a biopharmaceutical company that discovers and develops cell specific oligonucleotides as therapeutic agents for the treatment of central nervous system and neuromuscular disorders. The company’s lead candidate includes NLF-PD-1233, an oligonucle …
  • Verax Biomedical Inc：医療機器：M&Aディール及び事業提携情報
    Summary Verax Biomedical Inc (Verax) is a developer of rapid tests for the detection of bacterial contaminants in tissues for transplantation, blood components, and cellular therapies. The company’s products include platelet pgd test, red cell pgd test and cell therapy PGD test. It uses the PGD tech …
  • CHS Inc (CHSCP)：企業の財務・戦略的SWOT分析
    CHS Inc (CHSCP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Worldpay, Inc.：企業の財務・戦略的SWOT分析
    Worldpay, Inc. - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Sanovas Inc-医療機器分野：企業M&A・提携分析
    Summary Sanovas Inc (Sanovas) focuses on the development of minimally invasive diagnostic and therapeutic technologies and solutions. The company provides imaging technologies, interventional lung, interventional ENT, and interventional uro and gyn products. Its imaging technologies product provides …
  • Jersey Oil and Gas Plc (JOG)：石油・ガス：M&Aディール及び事業提携情報
    Summary Jersey Oil and Gas Plc (Jersey Oil), formerly Trap Oil Group Plc is an upstream oil and gas exploration and production company. The company acquires, explores, develops and produces natural gas properties in the UK continental shelf. Its oil and gas properties include Homer Block, Cortina Bl …
  • Mapletree Commercial Trust Management Ltd：企業の戦略・SWOT・財務情報
    Mapletree Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report Summary Mapletree Commercial Trust Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Constellium NV：企業の戦略・SWOT・財務分析
    Constellium NV - Strategy, SWOT and Corporate Finance Report Summary Constellium NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Abcodia Ltd：医療機器：M&Aディール及び事業提携情報
    Summary Abcodia Ltd (Abcodia) is a clinical stage company that offers commercial development of novel, scientifically validated tests for the early detection of cancer. The company offers Roca Test, a blood test for early ovarian cancer detection. It validates and discovers biomarkers for early diag …
  • Radiation Monitoring Devices Inc：製品パイプライン分析
    Summary Radiation Monitoring Devices Inc (RMD), a subsidiary of Dynasil Corporation of America is a research and development company that provides solutions for security, medical and industrial applications. The company’s products include scintillators, APDs, cesium iodide, solid state photomultipli …
  • Enyo Pharma SA：製薬・医療：M&Aディール及び事業提携情報
    Summary Enyo Pharma SA (Enyo Pharma) is a biopharmaceutical company that develops molecules modulating host functions for the treatment of acute and chronic viral infections. The company provides technology which develops tools combining biological experimentation and computational development to id …
  • Heidelberg Pharma AG (WL6)：企業の財務・戦略的SWOT分析
    Heidelberg Pharma AG (WL6) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Concho Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Concho Resources Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Concho Resources Inc (Concho) is an oil and gas company that acquires, develops and explores oil and natural gas properties. The company owns and operates exploration assets in the Permian Basin …
  • DTE Energy Co (DTE)：石油・ガス：M&Aディール及び事業提携情報
    Summary DTE Energy Company (DTE Energy) is a diversified energy company that develops and manages energy-related businesses and services. It has presence in the electricity value chain from generation, procurement, to transmission, distribution, and sales. The company procures, stores, and transport …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆